EDU 21 - Leveraging Anti-Tumor Immunity with Radiopharmaceutical Therapy (RPT) and Potential Combinatorial Approaches with RPT and Immunotherapy
MODERATOR(S)
Ariel Marciscano, MD - Massachusetts General Hospital
session DESCRIPTION
Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings. While there is long-standing interest in combining focal radiotherapy (e.g., external beam radiation therapy) with immunotherapy to generate systemic anti-tumor immune responses - there has been limited success in the translation of this approach to the clinic. In contrast, the systemic nature of RPT and distinct cellular and molecular mechanism of this modality offers an attractive partner for immune-based approaches. Promising preclinical and translational work has demonstrated that RPT can be immunostimulatory and synergistically combine with both EBRT and/or immunotherapy. Given several recent regulatory approvals, a growing number of clinical indications and increasing utilization in the clinic there is a need to characterize the immunogenicity of RPT in the clinic and to better understand how this modality can complement and/or be optimally combined with immune-based approaches to improve patient outcomes.
learning objectives
- To describe RPT as a modality and to review current clinical indications (FDA/regulatory approvals) and clinical trial landscape with an emphasis on combination approaches involving EBRT and/or Immunotherapy.
- To discuss potential immunological mechanisms of RPT and explain potential synergy and combinatorial effects with immunotherapy based on preclinical and translational data.
- To analyze and assess optimal approaches for the clinical integration of RPT + immunotherapy combination strategies to improve clinical outcomes. To determine potential avenues and multi-disciplinary pathways for radiation oncology to develop novel applications for RPT with a focus on immunotherapy/EBRT combinations.
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
10:45am - 12:00pm PT
Leveraging Anti-Tumor Immunity with Radiopharmaceutical Therapy (RPT) and Potential Combinatorial Approaches with RPT and Immunotherapy
Speaker: Ariel Marciscano, MD - Massachusetts General Hospital, Boston -
10:45am - 10:47am PT
Introductions
Speaker: Ariel Marciscano, MD - Massachusetts General Hospital, Boston -
10:47am - 11:02am PT
A Primer on Radiopharmaceutical Therapy
Speaker: Freddy Escorcia, MD, PhD - National Cancer Institute, National Institutes of Health, Bethesda -
11:02am - 11:17am PT
RPT in the Clinic: An Overview of Indications and Clinical Trials with a Focus on RPT/Immunotherapy Combinations
Speaker: Mallika Marar, MD, MBA - Stanford University, Palo Alto -
11:17am - 11:32am PT
Immune-based Mechanisms of RPT and Potential Synergies with Immunotherapy (and/or EBRT)
Speaker: Julie Constanzo, PhD - Institut Régional du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier -
11:32am - 11:47am PT
Future Directions/Potential Opportunities to Harness RPT and RPT Combinations to Improve Anti-tumor Immunity and Clinical Outcomes
Speaker: Ravi Patel, MD, PhD - University of Pittsburgh Medical Center, Pittsburgh -
11:47am - 12:00pm PT
Questions and Answers
Speaker: Ariel Marciscano, MD - Massachusetts General Hospital, Boston